Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics disclosed positive Phase 3 trial results for their dual GLP-1/GIP receptor agonist obesity drug, HRS9531, in a China-based study. Participants receiving the once-weekly injectable experienced a mean weight loss approaching 18% after 48 weeks, with a substantial proportion achieving over 20% reduction in body weight. Safety profile data indicate primarily mild to moderate gastrointestinal adverse events. Hengrui plans regulatory submission in China while Kailera prepares global clinical development with higher doses and prolonged treatment durations. The trial's success signals strong potential for a competitive entrant into the obesity therapeutics market, particularly as China-originated drugs increasingly influence global biopharma licensing dynamics.